Notice of Correction to Application and Submission Information and Review Criteria for RFA-HL-17-008 "Pulmonary and Cardiovascular Consequences of Inhaled Nicotine (R01)"

Notice Number: NOT-HL-15-286

Key Dates
Release Date:   November 25, 2015

Related Announcements
RFA-HL-17-008   

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

On November 17, 2015, the NHLBI issued Funding Opportunity Announcement (FOA) RFA-HL-17-008 "Pulmonary and Cardiovascular Consequences of Inhaled Nicotine (R01)".  This Notice provides specific submission information to applicants regarding the Senior/Key Person Profile and the Review Criteria.

The following section of the FOA are revised accordingly:

Currently Reads
Section IV. Application and Submission Information

2. Content and Form of Application Submission

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed. 

Modified to Read
Section IV. Application and Submission Information

2. Content and Form of Application Submission

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed. 
Where applicable to the proposed specific research aims, describe relevant expertise and experience in such areas as aerosol sciences, inhalation dosimetry, pharmacology, immunology, molecular biology, developmental biology, cardiology, and pulmonology.  Describe how proposed personnel will collaborate to provide relevant expertise.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Lisa Postow, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone:  301-435-0202
Email: lisa.postow@nih.gov